Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

van Hout, B A

Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. [electronic resource] - European heart journal Apr 1998 - D59-66 p. digital

Publication Type: Journal Article

0195-668X


Abciximab
Angioplasty, Balloon, Coronary--economics
Antibodies, Monoclonal--economics
Coronary Disease--drug therapy
Cost-Benefit Analysis
Humans
Immunoglobulin Fab Fragments--economics
Platelet Aggregation Inhibitors--economics
Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors
Randomized Controlled Trials as Topic
Treatment Outcome
United States